974 related articles for article (PubMed ID: 31707696)
1. Long-term survival and renal dysfunction in a patient with recurrent colorectal cancer treated with Bevacizumab.
Kataoka S; Nishikawa Y; Funakoshi T; Horimatsu T; Kondo N; Matsubara T; Yanagita M; Matsumoto S; Muto M
Clin J Gastroenterol; 2020 Jun; 13(3):316-319. PubMed ID: 31707696
[TBL] [Abstract][Full Text] [Related]
2. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer.
Petrioli R; Francini E; Cherri S; Torre P; Fiaschi AI; Miano ST; Marrelli D; Rovello F; Francini G
Clin Colorectal Cancer; 2018 Dec; 17(4):e663-e669. PubMed ID: 30153975
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women.
Su J; Lai J; Yang R; Xu B; Zhu Y; Zhao M; Yang C; Liang G
BMC Gastroenterol; 2019 Jan; 19(1):17. PubMed ID: 30683047
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
[TBL] [Abstract][Full Text] [Related]
6. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
Kotaka M; Iwamoto S; Satake H; Sakai D; Kudo T; Fukunaga M; Konishi K; Ide Y; Ikumoto T; Tsuji A; Sano Y; Kato T; Sugimoto N; Satoh T; Kanazawa A; Kurata T; Yamanaka T; Tomita N
Int J Clin Oncol; 2020 Aug; 25(8):1515-1522. PubMed ID: 32409917
[TBL] [Abstract][Full Text] [Related]
8. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine Plus Bevacizumab as First-Line Therapy for Patients with Metastatic Colorectal Cancer and Poor Performance Status.
Yamada Y; Yoshimatsu K; Yokomizo H; Okayama S; Satake M; Ida A; Maeda H; Shiozawa S
J Nippon Med Sch; 2021 Nov; 88(5):496-499. PubMed ID: 32999176
[TBL] [Abstract][Full Text] [Related]
10. Adverse effects of bevacizumab in metastatic colorectal cancer : a case report and literature review.
Willems E; Gerne L; George C; D'Hondt M
Acta Gastroenterol Belg; 2019; 82(2):322-325. PubMed ID: 31314196
[TBL] [Abstract][Full Text] [Related]
11. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
12. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
13. Synergistic therapeutic effect of low-dose bevacizumab with cisplatin-based chemotherapy for advanced or recurrent cervical cancer.
Liu CH; Kung YH; Chien-Fu Lin J; Chuang CM; Wu HH; Jiang LY; Shih YC; Wang PH; Chen YJ
J Chin Med Assoc; 2021 Dec; 84(12):1139-1144. PubMed ID: 34610623
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and Efficacy of Bevacizumab Monotherapy in Older Patients With Recurrent Ovarian Cancer.
Shintani D; Yoshida H; Yabuno A; Fujiwara K
In Vivo; 2020; 34(3):1451-1457. PubMed ID: 32354945
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bevacizumab combined with chemotherapy in the treatment of advanced colorectal cancer and the effect on its adverse reactions.
Zhou W; Su X; Sun L; Liu Y; Wang Z; Wang X; Yang Y
Pak J Pharm Sci; 2022 Jan; 35(1(Special)):381-386. PubMed ID: 35236652
[TBL] [Abstract][Full Text] [Related]
19. Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
Aparicio T; Bouché O; Francois E; Retornaz F; Barbier E; Taieb J; Kirscher S; Etienne PL; Faroux R; Khemissa Akouz F; El Hajbi F; Locher C; Rinaldi Y; Lecomte T; Lavau-Denes S; Baconnier M; Oden-Gangloff A; Genet D; Bedenne L; Paillaud E;
Eur J Cancer; 2018 Jul; 97():16-24. PubMed ID: 29777975
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802).
Suenaga M; Nishina T; Mizunuma N; Yasui H; Ura T; Denda T; Ikeda J; Esaki T; Nishisaki H; Takano Y; Sugiyama Y; Muro K
BMC Cancer; 2015 Mar; 15():176. PubMed ID: 25884814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
